Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous for the F508del-CFTR mutation; historical genotype must be documented in the participant's source documents.~* Percent predicted FEV1 \<40 of adjusted for age, sex, and height at Screening~Exclusion Criteria:~* Participant currently receiving invasive mechanical ventilation.~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant~* Any clinically significant laboratory abnormalities at screening that would interfere with the study assessments or pose an undue risk for the subject~* A 12-lead electrocardiograms (ECG) demonstrating QTcF \>450 msec at Screening~* History of solid organ or hematological transplantation~* History of alcohol or drug abuse in the past year~* Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening.~* Use of strong inhibitors, moderate inducers, or strong inducers of CYP3A~* Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at Screening and Day 1.~* Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements~* Use of beta blockers or the equivalent at Screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumacaftor/Ivacaftor combination (Type: EXPERIMENTAL): Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).